KURENAI

Kyoto University Research Information Repository

KYOTO UNIVERSITY

Title	Rho signaling research: history, current status and future directions
Author(s)	Narumiya, Shuh; Thumkeo, Dean
Citation	FEBS Letters (2018), 592(11): 1763-1776
Issue Date	2018-06
URL	http://hdl.handle.net/2433/233033
Right	© 2018 The Authors. FEBS Letters published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Type	Journal Article
Textversion	publisher

Kyoto University

Rho signaling research: history, current status and future directions

Shuh Narumiya and Dean Thumkeo

Department of Drug Discovery Medicine, Medical Innovation Center, Kyoto University Graduate School of Medicine, Japan

Correspondence

S. Narumiya, Department of Drug Discovery Medicine, Medical Innovation Center, Kyoto University Graduate School of Medicine, 53 Shogoin Kawaharacho, Sakyo-ku, Kyoto 606-8507, Japan
Fax: +81 75 752 9114
Tel: +81 75 366 7468
E-mail: snaru@mfour.med.kyoto-u.ac.jp

One of the main research areas in biology from the mid-1980s through the 1990s was the elucidation of signaling pathways governing cell responses. These studies brought, among other molecules, the small GTPase Rho to the epicenter. Rho signaling research has since expanded to all areas of biology and medicine. Here, we describe how Rho emerged as a key molecule governing cell morphogenesis and movement, how it was linked to actin reorganization, and how the study of Rho signaling has expanded from cultured cells to whole biological systems. We then give an overview of the current research status of Rho signaling in development, brain, cardiovascular system, immunity and cancer, and discuss the future directions of Rho signaling research, with emphasis on one Rho effector, ROCK*.

*The Rho GTPase family. Rho family GTPases have now expanded to contain 20 members. Amino acid sequences of 20 Rho GTPases found in human were aligned and the phylogenetic tree was generated by ClustalW2 software (EMBL-EBI) based on NJ algorithm. The subfamilies of the Rho GTPases are highlighted by the circle and labeled on the right side. Rho cited in this review refers to the original members of Rho subfamily, RhoA, RhoB and RhoC, that are C3 substrates, and, unless specified, not to other members of the Rho subfamily such as Rac, Cdc42, and Rnd.

Keywords: actin; actomyosin; C3 exoenzyme; myosin; Rho; ROCK; SRF; Y-27632

Abbreviations
ECM, extracellular matrix; LPA, lysophosphatidic acid; MLC, myosin light chain; MRTF, myocardin-related transcription factor; PBMCs, peripheral blood mononuclear cells; ROCK, Rho-associated coiled-coil containing kinase; SRF, serum response factor.

Discovery of Rho and botulinum C3 exoenzyme; the dawn of Rho research

In the mid-1980s, there was a transition in signal transduction research. While prototypes of transmembrane signaling such as heterotrimeric G proteins and G-protein coupled receptors, receptor tyrosine kinases, channels and transporters, had been identified and cloned, little was known on how the signals transmitted within the cell evoke cell responses such as proliferation, exocytosis and adhesion. Although involvement of GTP in some of these responses was reported, molecules bearing such GTP-dependent functions were far from identification. An exception was Ras, which had been identified as retrovirus-coded oncogenes encoding a 21 kDa GTP-binding protein, but its action mechanism also remained an enigma. In this situation, Madaule and Axel serendipitously identified the first Ras homolog in Aplysia, and named it Rho [1]. They further detected Rho genes in human and rat, and suggested that those of human possibly consist of three members, which were later named RhoA, B, and C. However, without any biological findings, little attention was paid to it.

One approach to discover mechanisms and principles working in biological processes is to find out pharmacological tools interfering with such processes by specifically targeting the molecules involved. Given the demonstrated usefulness of cholera toxin and pertussis toxin as probes of heterotrimeric G-proteins, Gs and Gi/Go, respectively [2] and the fact that most of the bacterial toxin ADP-ribosyltransferases target GTP-binding proteins [2], we sought a novel bacterial ADP-ribosyltransferase activity, and identified in preparations of botulinum C1 and D toxin an enzyme that ADP-ribosylates a 22 kDa GTP-binding protein in mammalian cells. We reported these findings in the *Journal of Biological Chemistry* on February 5, 1987 [3]. To our surprise, the same enzyme activity was reported in the February 9, 1987, issue of *FEBS Letters* by Aktories and collaborators [4]. They later further reported that this ADP-ribosyltransferase is distinct from botulinum neurotoxins and named it C3 exoenzyme [5]. Almost 1 year later, Rubin *et al.* confirmed these findings and additionally reported that the C3 treatment induced morphological changes in cultured cells, typically the rounding up of fibroblasts and epithelial cells and the neurite extension of neuronal cells [6], which we also noted separately [7,8]. However, the identity of the target GTP-binding protein was not elucidated until we purified and identified it as Rho [9–11]. Our studies thus merged researches

on Rho and C3. Chardin *et al.* then reported that actin microfilaments were lost in C3-treated round-up Vero cells [12]. The next question was therefore how the morphological phenotype of C3-treated cells is related to the function of Rho and how Rho is involved in actin microfilament assembly. Because little was known about the difference between the Rho isoforms, most of the early studies in the field were focused on RhoA.

Rho as a molecular switch for actin cytoskeleton reorganization

According to the analogy to Ras, it was thought that Rho is activated from the GDP-bound form to the GTP-bound form to exert its actions. So, the above question could be addressed by comparing the C3 phenotype with that induced by active Rho. This was exactly where Alan Hall and collaborators entered the field, using their expertise in Ras biochemistry and microinjection technique. They microinjected Val^{14}-RhoA, a presumably active RhoA mutant with reduced GTPase activity, and found extensive actin filament assembly in the contracted body of microinjected cells [13]. Although this Val^{14}-RhoA phenotype appeared opposite to the above phenotype of C3-treated cells, it was not clear at this time what kind of cell structures and what kind of cell response they represent. Ridley and Hall addressed these points [14]. They showed that the actin filament structure induced by active RhoA in fibroblasts represents actin stress fibers linked to focal adhesions, that these structures are induced by the addition of serum to the cells, and that this induction was inhibited by microinjection of C3 or ADP-ribosylated Rho, thus making clear that Rho works as a molecular switch in stimulus-induced stress fiber formation. By this time, homology cloning and protein purification identified a variety of Ras-related GTP-binding proteins in mammals and yeast. Didsbury *et al.* [15] isolated two cDNAs highly homologous to Rho from HL-60 kibrary, and erroneously named Rac (Ras-related C3 substrate) 1 and 2. Ridley and Hall therefore extended their study to examine the function of Rac1, and reported that Rac1 induces a different actin filament structure, membrane ruffles, in response to PDGF [16]. Their works thus established the paradigm that Rho GTPases function as molecular switches for actin reorganization.

Focal adhesion induced by Rho is the multi-protein complex of integrin and associated proteins, which is clustered by the force of actomyosin bundles ligated

to this complex, and serves as adhesion to extracellular matrix (ECM). Therefore, Rho-induced focal adhesion formation facilitates cell adhesion to ECM by increasing the integrin avidity. We confirmed RhoA action with platelet aggregation as an example, which is mediated by binding of platelet integrin GPIIb/IIIa to soluble ECM ligands such as fibrinogen [17].

Other notable examples of Rho-regulated cell processes were neurite retraction and cytokinesis. In the above work on stress fibers, Ridley and Hall identified a major RhoA activating factor in serum as lysophosphatidic acid (LPA). The biological activity of this lipid was found by Wouter Moolenaar, who also found that the addition of LPA induces neurite retraction in neuroblastoma cells. Hearing his talk at our Department seminar, we noticed that this LPA phenotype was opposite to neurite extension by the C3 treatment. We therefore collaborated and found that RhoA mediates neurite retraction induced by LPA [18]. We also collaborated with Issei Mabuchi on the role of Rho in cytokinesis, and found that the C3 treatment aborted cytokinesis by abolishing the contractile ring, indicating that Rho links nuclear division to cytoplasmic division through induction of the contractile ring [19]. Kishi *et al*. analyzed the division of Xenopus embryos and reached the same conclusion [20].

Intriguingly, Treisman and collaborators found that LPA also activates the transcription factor "serum response factor (SRF)" and this activation also requires functional RhoA [21]. Their later studies showed that SRF activity is regulated by SRF transcriptional coactivator myocardin-related transcription factor (MAL/MRTF) and that the interaction between SRF and MAL/MRTF is inhibited by the binding of MAL/MRTF to G-actin [22]. Upon RhoA activation, G-actin is incorporated into F-actin and MAL/MRTF is subsequently released from G-actin. This facilitates the formation of SRF-MAL/MRTF complexes and thus the activation of SRF-dependent transcription of genes that are involved in a variety of cellular processes such as cell migration, cell proliferation and cell differentiation [23].

Search and identification of Rho effectors; elucidation of molecular mechanisms of Rho actions

Both stress fibers and the contractile ring are composed of actomyosin bundles and neurite retraction is caused by their contraction. These findings led us to hypothesize that the action of Rho is to make actin filaments from actin monomers and then cross-link them

by activating myosin for contraction. So, the next issue of Rho research was to find out molecules and mechanisms underlying these steps, which are presumably carried out by effector molecules downstream of Rho. Since the GTP-bound and not GDP-bound Rho exerts its actions, effector molecules were presumed to bind selectively to the GTP-bound Rho. Isolation of small GTPase effectors by such selective binding was heralded by Louis Lim and collaborators, who isolated p65PAK (PAK1) as a Cdc42/Rac effector in 1994 [24]. Using selective binding to the GTP-bound Rho in ligand overlay assay or yeast two hybrid systems, we isolated several Rho effectors [25–29]. One of them is Rho-associated coiled-coil containing kinase (ROCK), which consists of two isoforms, ROCK-I (ROCK1) and ROCK-II (ROCK2) [26,30]. The same enzymes were isolated and called ROK and Rho-kinase by Louis Lim's group [31] and Kozo Kaibuchi's group [32], which correspond to ROCK-I and ROCK-II, respectively. Another effector we isolated was a mammalian homolog of *Diaphanous* (mDia) [29], which belongs to the formin family and consists of three isoforms [33]. Expression of active ROCK produced actomyosin bundles reminiscent of stress fibers and extensive formation of focal adhesions in HeLa cells [34,35] presumably through activation of myosin (see below), and expression of active mDia increased the density of actin filaments [29], suggesting that it induces actin polymerization. The actin nucleation/polymerization activity of the formin family was later shown in yeast formin, Bni1p [36] and then mDia [37]. Co-expression of ROCK and mDia produced beautifully aligned stress fibers in HeLa cells, thus reproducing the action of Rho on stress fiber formation [38]. Thus, mDia and ROCK are thought as main effectors in Rho-induced actin reorganization (Fig. 1).

Discovery of Y-27632, a specific ROCK inhibitor; a pivotal point from cell biology to physiology

Smooth muscle contraction is triggered by myosin light chain (MLC) phosphorylation. The involvement and mechanism of ROCK in myosin activation was revealed both biochemically and pharmacologically by the analysis of the so called "calcium-sensitization pathway" of smooth muscle contraction. This pathway augments contraction at a fixed intracellular calcium ion concentration $[Ca^{2+}]_I$, and was previously demonstrated to involve GTP, RhoA and myosin phosphatase [39,40]. Kaibuchi's group showed that Rho kinase/ROCK phosphorylates myosin-binding subunit of myosin phosphatase, thus inactivating the

Fig. 1. (A) Simplified scheme depicting the actions of mDia and ROCK in Rho-mediated actin remodeling. Upon the activation by Rho, mDia promotes actin nucleation and polymerization to form actin filaments and ROCK activates myosin to bundles actin filaments. The upper right box shows the FH1FH2 of mDia1-catalyzed actin polymerization *in vitro*. Red arrowheads indicate the mDia1-free barbed end of F-actin growing at slow rate, and blue arrowheads indicate the barbed end undergoing mDia1 (FH1FH2)-dependent fast growth. Times are indicated in seconds. Scale bar, 5 μm. Modified from *Yamashiro S, et al.* MBoC 25, 1010–1024 (2014). The lower right box shows F-actin staining of HeLa cells overexpressing vector control or active ROCK-I. Note that F-actin bundles are extensively induced in active ROCK-I overexpressed cells. Modified from *Ishizaki T, et al.* FEBS Lett. 404, 118–124 (1997). (B) Crystal structures of Y-27632-bound (left) and fasudil-bound (right) kinase domain of ROCK-I. Modified from *Jacobs M, et al.* JBC 281, 260–268 (2006).

phosphatase and consequently raising MLC phosphorylation and contraction [41]. The involvement of ROCK in this process was also confirmed pharmacologically using Y-27632. Y-27632 was developed as a compound that inhibits the calcium-sensitization pathway of smooth muscle contraction, and the photo-affinity cross-linking and the assay on recombinant ROCK identified it as a selective ROCK inhibitor [42]. This inhibitor not only inhibited the calcium-sensitization of smooth muscle selectively but also abolished RhoA-induced formation of stress fibers and focal adhesions. This compound further inhibits the RhoA-mediated neurite retraction in neuroblastoma cells and

analysis of this effect revealed the RhoA-mediated inhibition of actin depolymerization through the ROCK-LIM kinase-cofilin pathway [43]. Thus, identification of Rho effectors and a ROCK-specific inhibitor facilitated elucidation of molecular mechanisms of Rho-mediated cellular responses. The impact of the discovery of Y-27632, however, was not limited to analysis of cultured cells but also on intact animals, in which Y-27632 is used to examine possible involvement of Rho-ROCK signaling in various physiological and pathophysiological processes as described below. Thus, the discovery of Y-27632 made a pivotal point in Rho research.

Rho signaling research in current status

With the spread of the knowledge on Rho signaling in various cell processes and the advent of various dissecting tools, that is, drugs, expression constructs, RNAi and transgenic, and knockout animals, Rho signaling research has spread widely to all areas of biology. Here, we select several fields and overview their current status.

Development and regeneration

Rho signaling functions critically in several developmental processes (Fig. 2). Its typical mode of action here is to form actomyosin bundles traversed intercellularly by connecting neighboring epithelial cells through cell-cell adhesion and contract them for tissue morphogenesis and maintenance. Both ROCK and mDia are involved. For example, mice-deficient in either ROCK-I or ROCK-II fail in closure of the eyelid and the ventral body wall and are born with the 'eyes open at birth' and omphalocele phenotype. In these mice, actin cables that encircle the eye in the epithelial cells of the eyelid as well as those encircling the umbilical ring are disorganized [44–46]. Although each of ROCK-I and ROCK-II exhibits distinct roles in many circumstances described below, they apparently act functionally redundant in these closure processes. In mDia1/3 double KO mice, apical actin belts in neuroepithelial cells were attenuated and their apical adherens junctions were impaired, resulting in the loss of apical-basal polarity of neuroepithelial cells and periventricular hyperplasia [47]. When such apical actomyosin cables contract, it causes apical constriction of epithelial cells and, making cuboidal cells to trapezoid, bending tissues and forming three-dimensional structures such as tube and invagination. This is seen in gastrulation and neurulation, where Rho, ROCK and mDia function [48]. In chick neural tube formation, cadherin, Celsr1, recruits PDZ-RhoGEF at the mediolateral adherens junctions to upregulate Rho-ROCK signaling and cause actomyosin contraction apically in a planar-polarized manner [49,50]. A similar role of Rho-ROCK signaling in planar cell polarity was reported in Drosophila germ band extension [51]. Furthermore, ROCK functions also in making convex invagination in optic-cup-like structure formation from ES cells in culture [52]. In addition, the polarized localization of ROCK causes biased actomyosin activity in a single cell, and this mechanism operates crucially in asymmetric cell division of Drosophila neural stem cells [53].

YAP and TAZ are effectors of the Hippo signaling involved in control of organ size, stem cell renewal, regeneration and cancer [54]. They are also involved in mechanotransduction, and translocate to the nucleus on sensing of ECM stiffness and cell spreading in Rho- and actomyosin tension-dependent manners [55]. Requirement of Rho signaling is also observed in activation of YAP/TAZ by Wnt signaling, in which Wnt activates Rho through FZD-ROR-Gα12/13 pathway and inhibits Lats1/2 [56]. This Rho-mediated activation of YAP/TAZ is required for long-term survival and expansion of human ES cells cultured *en bloc* [57]. Interestingly and paradoxically, dissociated human ES cells exhibit Rho-ROCK-mediated hyperactivation of myosin and the resultant contraction induces their death, which can be rescued by Y-27632 [58–60].

Brain morphogenesis and function

Rho signaling is involved in brain morphogenesis and functions including axonogenesis, neuronal migration and synaptic plasticity. Neurite retraction in cultured neuron is mediated by ROCK [61,62] and ROCK2 KO mice exhibited enhanced axonogenesis after spinal cord injury and recovered faster than the control mice [63]. The Rho-ROCK signaling is now recognized as the final common pathway to limit axonogenesis in CNS trauma and the potential of ROCK inhibitor in axonal regeneration is being examined [64]. Notably, this Rho-ROCK action operates in not only such pathophysiological process but also neuronal development. Kaibuchi's group recently showed that the growing axon transmits long-range Ca^{2+} waves to other neurites, activates RhoA-ROCK pathway there and suppresses their axonogenesis to allow the formation of a single axon in neurons [65]. Rho signaling also works in neuronal migration; mice deficient in mDia1 and 3 in combination exhibit deficit in tangential migration of interneuron precursors from subventricular zone to the olfactory bulb [66]. Moreover, Rho signaling plays critical roles in synaptic plasticity. The dendritic spine is the site of memory. Rac and Rho work antagonistically in shaping dendritic spines, growth and shrinkage, respectively, and ROCK mediates the latter Rho action [67]. By this action, ROCK apparently is involved in some types of mental retardation, where a Rho GTPase activating protein named oligophrenin-1 is mutated; down-regulation of oligophrenin-1 results in spine shrinkage, which is rescued by ROCK inhibitor [68]. In addition to these postsynaptic actions, ROCK functions in synaptic vesicle retrieval in the presynaptic terminal to contribute to the homeostatic balance of vesicle exocytosis and

Fig. 2. Examples of the ROCK actions in development. The left box shows the impaired eyelid closure phenotype of ROCK-I$^{-/-}$ embryos. Scanning electron micrographs of the eyes of the WT and ROCK-I$^{-/-}$ embryos are shown on the top and whole-mount F-actin staining of the eyelids of WT and ROCK-I$^{-/-}$ embryos are shown on the bottom. Note that F-actin bundles encircling the eye (arrowheads) are impaired in ROCK-I$^{-/-}$ embryos. Modified from *Shimizu Y, et al.* JCB 168, 941–953 (2005). The right box shows the role of ROCK in neural tube closure. H&E staining of mouse embryo neural tube is shown on the top left (H. Kamijo, T. Ishizaki, D. Thumkeo, S. Narumiya, *et al.*, unpublished results). The upper three panels show immunofluorescence micrographs of chick embryo neural tube during neural tube closure. Modified from *Nishimura T, et al.* Development 141, 1987–1998 (2008) and *Nishimura T, et al.* Cell 149, 1084–1097 (2012). Note concentration of ROCK-I and pMLC on the apical surface as marked by ZO-1 staining. The lower panels show stereomicroscope micrographs of 9.5 dpc mouse embryo neural tube (H. Kamijo, T. Ishizaki, D. Thumkeo, S. Narumiya, *et al.*, unpublished results). Note impaired neural tube closure of ROCK-I$^{+/-}$; ROCK-II$^{-/-}$ mouse embryo (white arrow). A model proposes the role of ROCK-mediated actomyosin on the apical surface of neuroepithelium during neural tube closure is shown on the bottom right.

endocytosis at synapse [69]. Furthermore, Rho signaling is involved in plasticity of the presynaptic terminal. Deguchi *et al.* [70] found that social isolation of mice induces inactivation of *Nucleus accumbens* neurons, which then leads to mDia and ROCK-dependent contraction of their terminals in the *Ventral tegmental area* and reduces synaptic transmission there, which causes enhanced anxiety behavior in these animals. These actions of Rho-ROCK signaling could be involved in synaptic plasticity in the lateral amygdala associated with fear conditioning as well as that in prelimbic prefrontal cortex associated with goal-directed decision making, both of which is sensitive to ROCK inhibition [71,72].

Cardiovascular system

Since Y-27632 was discovered through screening for compounds that inhibit calcium sensitization of arterial contraction and shown to lower blood pressure in various rat models of hypertension [42], much interest has arisen naturally in the role of Rho-ROCK signaling in the cardiovascular system. Such interest was boosted further by the finding that fasudil, a drug

approved in Japan for treatment of vasospasm after subarachnoid hemorrhage, is also a ROCK inhibitor [73], which has stimulated studies not only in animals but also in humans. For example, fasudil is effective in decreasing the frequency of attacks in stable angina patients [74] and attenuating coronary artery vasospasm in patients with vasospastic angina, the effect reproduced in the porcine model with enhanced myosin phosphatase activation [75]. These findings led to the proposal of a role of ROCK in coronary vasospasm. In idiopathic pulmonary hypertension, ROCK2 is highly expressed in pulmonary arteries of patients and fasudil treatment induces acute pulmonary vasodilation [76]. Consistently, the selective loss of ROCK2 in vascular smooth muscle prevents development of chronic hypoxia-induced pulmonary hypertension in mice, suggesting the causative relation of ROCK2 in this disease. Other studies using ROCK1 and ROCK2 KO mice and ROCK inhibitors in various animal models indicate the involvement of ROCK in diabetic vasculopathy, ischemia/reperfusion injury, heart failure, cardiac hypertrophy, and fibrosis [77]. Interestingly, in aortic constriction model, the cardiomyocyte-specific deletion of ROCK2 suppressed the cardiac hypertrophy [78], while the ROCK1 haploinsufficiency did not prevent cardiac hypertrophy but reduced fibrosis under the same condition [79]. A profibrotic role of ROCK is also reported in various organs including lung [80].

Immunity

Early studies on the role of Rho in the immune system focused on its role in development, activation and migration of T cells and B cells [81]. For example, studies on mice expressing C3 or active RhoA in T cell lineages suggested that Rho is important in thymocyte expansion but dispensable for T cell development itself [82,83]. Indeed, deficiency of RhoA in T cells does not completely suppress but significantly attenuates in T cell receptor-dependent proliferative response [84]. Inactivation of Rho and treatment with ROCK inhibitors impairs T cell migration. The most notable feature is deficit in transendothelial migration due to impaired uropod retraction [85], a feature shared with neural precursors, macrophages, neutrophils and cancer cells [66,86–88]. Recent studies have focused more on the role of ROCK in the differentiation of T helper cell (Th) subsets and its pathological significance [89]. Rho-ROCK signaling appears to function in both the sensitization phase and effector phase of Th2-dependent allergic inflammation. T cell-specific deletion of

RhoA impaired Th2 differentiation but not Th1 differentiation *in vitro* and prevented OVA-induced allergic inflammation *in vivo* with reduction in IgE level, cell infiltration in the airway and Th2 cytokine production [84]. Administration of fasudil all through the experimental period mimicked these effects of RhoA deficiency. In addition, inhalation of Y-27632 during the allergen challenge could suppress airway constriction and hypersensitivity and partially prevented cell infiltration to the airway in an OVA-induced asthma model of guinea pig [90]. These effects of Y-27632 may well be due to the suppression of enhanced calcium sensitization of airway smooth muscle contraction induced by allergen-sensitization [91], and effects of ROCK inhibition on chemotaxis of inflammatory cells. Studies using ROCK hetero-deficient mice indicate that both ROCK1 and ROCK2 in lymphocytes and nonlymphocyte cells are involved in these processes [92,93].

The more intriguing findings on the role of ROCK in Th subsets are that of ROCK2 in Th17 cells. This was first reported by the Pernis group, who found that ROCK2 is selectively activated in CD4$^+$ T cells under Th17 skewing conditions and phosphorylates interferon regulatory factor-4 (IRF-4) to facilitate Th17 cell differentiation and that administration of ROCK inhibitor suppresses production of Th17 cytokines, IL-21 and IL-17, and ameliorates symptoms in autoimmune model mice [94]. Concurrently, Kadmon Pharmaceuticals ran Phase 1 clinical trial of a ROCK2-selective inhibitor, KD025 [95,96]. Zanin-Zhorov *et al.* [96] analyzed responses of peripheral blood mononuclear cells (PBMCs) from human subjects in the above trial and found that KD025 administration *in vivo* significantly inhibited *ex vivo* secretion of IL-21 and IL-17 from activated PBMCs. They confirmed this effect in human CD4$^+$ T cells stimulated *in vitro* under the Th17 skewing conditions, and found that it is through suppression of STAT3 phosphorylation. Intriguingly, while KD025 suppresses Th17 differentiation through decreased STAT3 phosphorylation, it accelerates regulatory T cell (Treg) differentiation through enhanced STAT5 phosphorylation. The effect of KD025 to suppress IL-17 and IL-21 production was then confirmed in PBMCs from patients with rheumatoid arthritis, graft-versus-host disease, systemic lupus erythematosus and inflammatory bowel diseases [96–99]. Further, recent Phase 2 studies showed that oral administration of KD025 reduces clinical scores in psoriasis patients with concomitant decrease in plasma levels of IL-17 and IL-23 and increase in that of IL-10 [100].

Cancer

Since many *dbl*-containing Rho GEFs were isolated by transformation assay of cultured fibroblasts [101] and Rho-GAP domain-containing DLC-1 (Deleted in Liver Cancer-1) is downregulated in various tumors and is regarded as a tumor suppressor [102], Rho GTPases have been implicated in cell transformation and oncogenesis. Indeed, earlier works showed requirement of Rho GTPases in Ras-mediated cell-transformation [103]. Notably, while these studies used GTPase-deficient G14V or Q63L in RhoA and G12V or Q61L Rac1 analogous to oncogenic Ras mutations, such mutations in Rho GTPases have not been detected in clinical cancer. On the contrary, fast cycling P29S, P29L, and P29Q mutations in Rac1 have been identified by high-throughput sequencing of clinical human cancers [104–106], the G17V RhoA mutation frequent found in T cell lymphomas [107,108] and the Y42C RhoA mutation recurrently in diffuse gastric cancer [109]. Since biochemical properties of these RhoA mutation are not clear, how these RhoA mutations induces oncogenesis is an interesting question to be solved [110]. In addition to these mutations in Rho GTPases, more than 600 somatic coding mutations in ROCK1 and ROCK2 have been identified in human cancers and downregulation of miRNAs targeting ROCK1 and ROCK2, and, consequently upregulation of ROCKs has been shown in malignant tissues [111]. This enhanced ROCK signaling could facilitate cell transformation for tumor cell survival and growth. Y-27632 treatment was reported to inhibit transformation of NIH3T3 cells by Dbl and Ras [112], and conditional deletion of ROCK1 and ROCK2 in combination was shown to inhibit transformation of cells derived from Ras-driven lung tumors and Raf-driven melanomas [113]. ROCK signaling likely functions in tumor cell invasion and metastasis, which was first shown in the peritoneal tumor dissemination model [88]. Tumor cells can migrate as single cells or collectively as a cluster. Experiments in three-dimensional matrix suggest that tumor cells adopt two different modes of single-cell migratory mechanisms, Rac-mediated elongated mesenchymal migration and ROCK-mediated rounded amoeboid migration, which are interconvertible and utilized in the context-dependent manner [114]. ROCK signaling also enables tail retraction in transendothelial and transepithelial migration of tumor cells [88]. ROCK can also remodel extracellular matrix in tumor microenvironment for tumor invasion. Sanz-Moreno *et al*. [115] showed in collagen matrix model that increased ROCK signaling induced by cytokine contracts stromal fibroblasts to create tracks for collective migration of squamous carcinoma cells. Rath *et al*. [116] showed that ROCK activation in mouse pancreatic ductal adenocarcinoma cells increased their invasive growth into a three-dimensional collagen matrix by extensive induction of matrix metalloproteinases and increased matrix remodeling. These findings combined together suggest that


Fig. 3. Milestone discoveries in Rho signaling research.

Rho-ROCK signaling is not the primary cause but critical for several important phenotypes of cancer, which may be exploited therapeutically in combination with other anticancer therapies [111].

Future prospects

Although a substantial amount of work has been done since the discovery of Rho more than 30 years ago, elucidating important physiological roles of this GTPase family and their action mechanisms as described above (Fig. 3), the whole picture of the biology of Rho, how each member of the Rho family GTPases is activated under what conditions in which tissue, exerts which body function by acting on which effectors, is still far from complete. Generation and analysis of tissue-specific conditional knockout mice deficient in each member of Rho GTPases, effectors and regulatory proteins, GEFs and GAPs, could help our understanding. This is true even for each of classic Rho member, RhoA, RhoB, and RhoC. Most of the earlier studies on Rho described above have been carried out on RhoA, and it is not certain whether other Rho members exert the same actions in the cell. Although some studies suggest the redundant roles between these RhoA, RhoB, and RhoC isoforms [117,118], their different cellular localization and different regulatory modes of expression strongly suggest that they play also context- and localization-dependent distinct roles in the cell and possibly in the body [119]. For example, although these three Rho members similarly interact with Rho effectors thus far identified, RhoA, RhoB, and RhoC act on different effectors, namely ROCKi/2, integrins and formin FMNL3, respectively, and exert different functions in cancer cell migration and morphogenesis [120]. RhoB shows unique endosome localization, and is suggested to exert different functions from RhoA and RhoC [121]. Furthermore, while RhoA-null mice are embryonic lethal [122], RhoB-null and RhoC-null mice are viable [123,124]. There are also issues on atypical Rho GTPases such as Rnd proteins, RhoBTB proteins, RhoH, RhoU and RhoV [119]. More remains to be clarified on their regulatory and effector mechanisms, and again their body function. As for Rho GTPase activation, there are 70 Rho GEFs of Dbl homology and 10 DOCK homologs. Studies have been in progress elucidating what physiological context each GEF is activated and contributes to, one classic examples being p115 RhoA-GEF coupling to Gα12/13 for cell contraction [125]. Given such importance of Rho and Rho regulators and effectors in many biological processes, the studies on the dynamics of their activation

and termination, that is how Rho and Rho regulators and effectors are activated at the right time and place, and how this signal propagates in the living cell in a variety of physiological processes, is an important issue. The challenge is nanoscale imaging of spatiotemporal actions of Rho-Rho effectors not only in living cultured cells but also hopefully in intact tissues or intact body. Such studies combined with the systematic analysis on the functions of Rho signaling at respective sites will help to elucidate the pictures of Rho actions in the body. Finally, our understanding on the roles of Rho and Rho effectors in pathophysiology has just begun. As illustrated by the recent discovery of the role of ROCK2 in autoimmunity and the therapeutic effects of its selective inhibitor [100], unraveling the roles of Rho and Rho effectors further in various pathophysiological settings by the above approach may reveal unappreciated therapeutic possibilities.

Acknowledgements

References

1 Madaule P and Axel R (1985) A novel ras-related gene family. *Cell* **41**, 31–40.

2 Moss J and Vaughan M (1988) ADP-ribosylation of guanyl nucleotide-binding regulatory proteins by bacterial toxins. *Adv Enzymol Relat Areas Mol Biol* **61**, 303–379.

3 Ohashi Y and Narumiya S (1987) ADP-ribosylation of a Mr 21,000 membrane protein by type D botulinum toxin. *J Biol Chem* **262**, 1430–1433.

4 Aktories K, Weller U and Chhatwal GS (1987) *Clostridium botulinum* type C produces a novel ADP-ribosyltransferase distinct from botulinum C2 toxin. *FEBS Lett* **212**, 109–113.

5 Rosener S, Chhatwal GS and Aktories K (1987) Botulinum ADP-ribosyltransferase C3 but not botulinum neurotoxins C1 and D ADP-ribosylates low molecular mass GTP-binding proteins. *FEBS Lett* **224**, 38–42.

6 Rubin EJ, Gill DM, Boquet P and Popoff MR (1988) Functional modification of a 21-kilodalton G protein when ADP-ribosylated by exoenzyme C3 of *Clostridium botulinum*. *Mol Cell Biol* **8**, 418–426.

7 Nishiki T, Matsuda H, Hiroi T, Kamata Y, Kozaki S, Narumiya S and Sakaguchi G (1990) Morphological effects of *Clostridium botulinum* C3 exoenzyme on cultured cells. *Jpn J Med Sci Biol* **43**, 261–262.

8 Nishiki T, Narumiya S, Morii N, Yamamoto M, Fujiwara M, Kamata Y, Sakaguchi G and Kozaki S (1990) ADP-ribosylation of the rho/rac proteins induces growth inhibition, neurite outgrowth and acetylcholine esterase in cultured PC-12 cells. *Biochem Biophys Res Commun* **167**, 265–272.

9 Morii N, Sekine A, Ohashi Y, Nakao K, Imura H, Fujiwara M and Narumiya S (1988) Purification and properties of the cytosolic substrate for botulinum ADP-ribosyltransferase. Identification as an Mr 22,000 guanine nucleotide-binding protein. *J Biol Chem* **263**, 12420–12426.

10 Narumiya S, Sekine M and Fujiwara M (1988) Substrate for botulinum ADP-ribosyltransferase, Gb, has an amino acid sequence homologous to a putative rho gene product. *J Biol Chem* **263**, 17255–17257.

11 Sekine A, Fujiwara M and Narumiya S (1989) Asparagine residue in the rho gene product is the modification site for botulinum ADP-ribosyltransferase. *J Biol Chem* **264**, 8602–8605.

12 Chardin P, Boquet P, Madaule P, Popoff MR, Rubin EJ and Gill DM (1989) The mammalian G protein rhoC is ADP-ribosylated by *Clostridium botulinum* exoenzyme C3 and affects actin microfilaments in Vero cells. *EMBO J* **8**, 1087–1092.

13 Paterson HF, Self AJ, Garrett MD, Just I, Aktories K and Hall A (1990) Microinjection of recombinant p21rho induces rapid changes in cell morphology. *J Cell Biol* **111**, 1001–1007.

14 Ridley AJ and Hall A (1992) The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. *Cell* **70**, 389–399.

15 Didsbury J, Weber RF, Bokoch GM, Evans T and Snyderman R (1989) rac, a novel ras-related family of proteins that are botulinum toxin substrates. *J Biol Chem* **264**, 16378–16382.

16 Ridley AJ, Paterson HF, Johnston CL, Diekmann D and Hall A (1992) The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. *Cell* **70**, 401–410.

17 Morii N, Teru-uchi T, Tominaga T, Kumagai N, Kozaki S, Ushikubi F and Narumiya S (1992) A rho gene product in human blood platelets. II. Effects of the ADP-ribosylation by botulinum C3 ADP-ribosyltransferase on platelet aggregation. *J Biol Chem* **267**, 20921–20926.

18 Jalink K, van Corven EJ, Hengeveld T, Morii N, Narumiya S and Moolenaar WH (1994) Inhibition of lysophosphatidate- and thrombin-induced neurite retraction and neuronal cell rounding by ADP ribosylation of the small GTP-binding protein Rho. *J Cell Biol* **126**, 801–810.

19 Mabuchi I, Hamaguchi Y, Fujimoto H, Morii N, Mishima M and Narumiya S (1993) A rho-like protein is involved in the organisation of the contractile ring in dividing sand dollar eggs. *Zygote* **1**, 325–331.

20 Kishi K, Sasaki T, Kuroda S, Itoh T and Takai Y (1993) Regulation of cytoplasmic division of Xenopus embryo by rho p21 and its inhibitory GDP/GTP exchange protein (rho GDI). *J Cell Biol* **120**, 1187–1195.

21 Hills CS, Wynne J and Treisman R (1995) The Rho family GTPases RhoA, Rac1, and CDC42Hs regulate transcriptional activation by SRF. *Cell* **81**, 1159–1170.

22 Miralles F, Posern G, Zaromytidou A and Treisman R (2003) Actin dynamics control SRF activity by regulation of its coactivator MAL. *Cell* **113**, 329–342.

23 Posern G and Treisman R (2006) Actin' together: serum response factor, its cofactors and the link to signal transduction. *Trends Cell Biol* **16**, 588–596.

24 Manser E, Leung T, Salihuddin H, Zhao ZS and Lim L (1994) A brain serine/threonine protein kinase activated by Cdc42 and Rac1. *Nature* **367**, 40–46.

25 Madaule P, Furuyashiki T, Reid T, Ishizaki T, Watanabe G, Morii N and Narumiya S (1995) A novel partner for the GTP-bound forms of rho and rac. *FEBS Lett* **377**, 243–248.

26 Ishizaki T, Maekawa M, Fujisawa K, Okawa K, Iwamatsu A, Fujita A, Watanabe N, Saito Y, Kakizuka A, Morii N *et al.* (1996) The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. *EMBO J* **15**, 1885–1893.

27 Watanabe G, Saito Y, Madaule P, Ishizaki T, Fujisawa K, Morii N, Mukai H, Ono Y, Kakizuka A and Narumiya S (1996) Protein kinase N (PKN) and PKN-related protein rhophilin as targets of small GTPase Rho. *Science* **271**, 645–648.

28 Reid T, Furuyashiki T, Ishizaki T, Watanabe G, Watanabe N, Fujisawa K, Morii N, Madaule P and Narumiya S (1996) Rhotekin, a new putative target for Rho bearing homology to a serine/threonine kinase, PKN, and rhophilin in the rho-binding domain. *J Biol Chem* **271**, 13556–13560.

29 Watanabe N, Madaule P, Reid T, Ishizaki T, Watanabe G, Kakizuka A, Saito Y, Nakao K, Jockusch BM and Narumiya S (1997) p140mDia, a mammalian homolog of Drosophila diaphanous, is a target protein for Rho small GTPase and is a ligand for profilin. *EMBO J* **16**, 3044–3056.

30 Nakagawa O, Fujisawa K, Ishizaki T, Saito Y, Nakao K and Narumiya S (1996) ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. *FEBS Lett* **392**, 189–193.

31 Leung T, Chen XQ, Manser E and Lim L (1996) The p160 RhoA-binding kinase ROK alpha is a member of a kinase family and is involved in the reorganization of the cytoskeleton. *Mol Cell Biol* **16**, 5313–5327.

32 Matsui T, Amano M, Yamamoto T, Chihara K, Nakafuku M, Ito M, Nakano T, Okawa K, Iwamatsu A and Kaibuchi K (1996) Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. *EMBO J* **15**, 2208–2216.

33 Thumkeo D, Watanabe S and Narumiya S (2013) Physiological roles of Rho and Rho effectors in mammals. *Eur J Cell Biol* **92**, 303–315.

34 Ishizaki T, Naito M, Fujisawa K, Maekawa M, Watanabe N, Saito Y and Narumiya S (1997) p160ROCK, a Rho-associated coiled-coil forming protein kinase, works downstream of Rho and induces focal adhesions. *FEBS Lett* **404**, 118–124.

35 Amano M, Chihara K, Kimura K, Fukata Y, Nakamura N, Matsuura Y and Kaibuchi K (1997) Formation of actin stress fibers and focal adhesions enhanced by Rho-kinase. *Science* **275**, 1308–1311.

36 Pruyne D, Evangelista M, Yang C, Bi E, Zigmond S, Bretscher A and Boone C (2002) Role of formins in actin assembly: nucleation and barbed-end association. *Science* **297**, 612–615.

37 Higashida C, Miyoshi T, Fujita A, Oceguera-Yanez F, Monypenny J, Andou Y, Narumiya S and Watanabe N (2004) Actin polymerization-driven molecular movement of mDia1 in living cell. *Science* **303**, 2007–2010.

38 Watanabe N, Kato T, Fujita A, Ishizaki T and Narumiya S (1999) Cooperation between mDia1 and ROCK in Rho-induced actin reorganization. *Nat Cell Biol* **1**, 136–143.

39 Kitazawa T, Masuo M and Somlyo AP (1991) G protein-mediated inhibition of myosin light-chain phosphatase in vascular smooth muscle. *Proc Natl Acad Sci USA* **88**, 9307–9310.

40 Hirata K, Kikuchi A, Sasaki T, Kuroda S, Kaibuchi K, Matsuura Y, Seki H, Saida K and Takai Y (1992) Involvement of rho p21 in the GTP-enhanced calcium ion sensitivity of smooth muscle contraction. *J Biol Chem* **267**, 8719–8722.

41 Kimura K, Ito M, Amano M, Chihara K, Fukata Y, Nakafuku M, Yamamori B, Feng J, Nakano T, Okawa K *et al.* (1996) Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). *Science* **273**, 245–248.

42 Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, Yamagami K, Inui J, Maekawa M *et al.* (1997) Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. *Nature* **389**, 990–994.

43 Maekawa M, Ishizaki T, Boku S, Watanabe N, Fujita A, Iwamatsu A, Obinata T, Ohashi K, Mizuno K and Narumiya S (1999) Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. *Science* **285**, 895–898.

44 Shimizu Y, Thumkeo D, Keel J, Ishizaki T, Oshima H, Oshima M, Noda Y, Atsumura F, Taketo MM & Narumiya S (2005) ROCK-I regulates closure of the eyelids and ventral body wall by inducing assembly of actomyosin bundles. *J Cell Biol* **168**, 941–953.

45 Thumkeo D, Keel J, Ishizaki T, Hirose M, Nonomura K, Oshima H, Oshima M, Taketo MM and Narumiya S (2003) Targeted disruption of the mouse rho-associated kinase 2 gene results in intrauterine growth retardation and fetal death. *Mol Cell Biol* **23**, 5043–5055.

46 Thumkeo D, Shimizu Y, Sakamoto S, Yamada S and Narumiya S (2005) ROCK-I and ROCK-II cooperatively regulate closure of eyelid and ventral body wall in mouse embryo. *Genes Cells* **10**, 825–834.

47 Thumkeo D, Shinohara R, Watanabe K, Takebayashi H, Toyoda Y, Tohyama K, Ishizaki T, Furuyashiki T and Narumiya S (2011) Deficiency of mDia, an actin nucleator, disrupts integrity of neuroepithelium and causes periventricular dysplasia. *PLoS One* **6**, e25465.

48 Martin AC and Goldstein B (2014) Apical constriction: themes and variations on a cellular mechanism driving morphogenesis. *Development* **141**, 1987–1998.

49 Nishimura T and Takeichi M (2008) Shroom3-mediated recruitment of Rho kinases to the apical cell junctions regulates epithelial and neuroepithelial planar remodeling. *Development* **135**, 1493–1502.

50 Nishimura T, Honda H and Takeichi M (2012) Planar cell polarity links axes of spatial dynamics in neural-tube closure. *Cell* **149**, 1084–1097.

51 Munjal A, Philippe JM, Munro E and Lecuit T (2015) A self-organized biomechanical network drives shape changes during tissue morphogenesis. *Nature* **524**, 351–355.

52 Eiraku M, Takata N, Ishibashi H, Kawada M, Sakakura E, Okuda S, Sekiguchi K, Adachi T and Sasai Y (2011) Self-organizing optic-cup morphogenesis in three-dimensional culture. *Nature* **472**, 51–56.

53 Tsankova A, Pham TT, Garcia DS, Otte F and Cabernard C (2017) Cell polarity regulates biased myosin activity and dynamics during asymmetric cell division via Drosophila Rho Kinase and Protein Kinase N. *Dev Cell* **42**, 143–155 e5.

54 Yu FX, Zhao B and Guan KL (2015) Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer. *Cell* **163**, 811–828.

55 Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M, Zanconato F, Le Digabel J, Forcato M, Bicciato S *et al.* (2011) Role of YAP/TAZ in mechanotransduction. *Nature* **474**, 179–183.

56 Park HW, Kim YC, Yu B, Moroishi T, Mo JS, Plouffe SW, Meng Z, Lin KC, Yu FX, Alexander CM *et al.* (2015) Alternative Wnt signaling activates YAP/TAZ. *Cell* **162**, 780–794.

57 Ohgushi M, Minaguchi M and Sasai Y (2015) Rho-signaling-directed YAP/TAZ activity underlies the long-term survival and expansion of human embryonic stem cells. *Cell Stem Cell* **17**, 448–461.

58 Watanabe K, Ueno M, Kamiya D, Nishiyama A, Matsumura M, Wataya T, Takahashi JB, Nishikawa S, Nishikawa S, Muguruma K *et al.* (2007) A ROCK inhibitor permits survival of dissociated human embryonic stem cells. *Nat Biotechnol* **25**, 681–686.

59 Koyanagi M, Takahashi J, Arakawa Y, Doi D, Fukuda H, Hayashi H, Narumiya S and Hashimoto N (2008) Inhibition of the Rho/ROCK pathway reduces apoptosis during transplantation of embryonic stem cell-derived neural precursors. *J Neurosci Res* **86**, 270–280.

60 Ohgushi M, Matsumura M, Eiraku M, Murakami K, Aramaki T, Nishiyama A, Muguruma K, Nakano T, Suga H, Ueno M *et al.* (2010) Molecular pathway and cell state responsible for dissociation-induced apoptosis in human pluripotent stem cells. *Cell Stem Cell* **7**, 225–239.

61 Hirose M, Ishizaki T, Watanabe N, Uehata M, Kranenburg O, Moolenaar WH, Matsumura F, Maekawa M, Bito H and Narumiya S (1998) Molecular dissection of the Rho-associated protein kinase (p160ROCK)-regulated neurite remodeling in neuroblastoma N1E-115 cells. *J Cell Biol* **141**, 1625–1636.

62 Bito H, Furuyashiki T, Ishihara H, Shibasaki Y, Ohashi K, Mizuno K, Maekawa M, Ishizaki T and Narumiya S (2000) A critical role for a Rho-associated kinase, p160ROCK, in determining axon outgrowth in mammalian CNS neurons. *Neuron* **26**, 431–441.

63 Duffy P, Schmandke A, Schmandke A, Sigworth J, Narumiya S, Cafferty WB and Strittmatter SM (2009) Rho-associated kinase II (ROCKII) limits axonal growth after trauma within the adult mouse spinal cord. *J Neurosci* **29**, 15266–15276.

64 Fujita Y and Yamashita T (2014) Axon growth inhibition by RhoA/ROCK in the central nervous system. *Front Neurosci* **8**, 338.

65 Takano T, Wu M, Nakamuta S, Naoki H, Ishizawa N, Namba T, Watanabe T, Xu C, Hamaguchi T, Yura Y *et al.* (2017) Discovery of long-range inhibitory signaling to ensure single axon formation. *Nat Commun* **8**, 33.

66 Shinohara R, Thumkeo D, Kamijo H, Kaneko N, Sawamoto K, Watanabe K, Takebayashi H, Kiyonari H, Ishizaki T, Furuyashiki T *et al.* (2012) A role for mDia, a Rho-regulated actin nucleator, in tangential migration of interneuron precursors. *Nat Neurosci* **15**, 373–380.

67 Tashiro A, Minden A and Yuste R (2000) Regulation of dendritic spine morphology by the rho family of small GTPases: antagonistic roles of Rac and Rho. *Cereb Cortex* **10**, 927–938.

68 Govek EE, Newey SE, Akerman CJ, Cross JR, Van der Veken L and Van Aelst L (2004) The X-linked mental retardation protein oligophrenin-1 is required for dendritic spine morphogenesis. *Nat Neurosci* **7**, 364–372.

69 Taoufiq Z, Eguchi K and Takahashi T (2013) Rho-kinase accelerates synaptic vesicle endocytosis by linking cyclic GMP-dependent protein kinase activity to phosphatidylinositol-4,5-bisphosphate synthesis. *J Neurosci* **33**, 12099–12104.

70 Deguchi Y, Harada M, Shinohara R, Lazarus M, Cherasse Y, Urade Y, Yamada D, Sekiguchi M, Watanabe D, Furuyashiki T *et al.* (2016) mDia and ROCK mediate actin-dependent presynaptic remodeling regulating synaptic efficacy and anxiety. *Cell Rep* **17**, 2405–2417.

71 Lamprecht R, Farb CR and LeDoux JE (2002) Fear memory formation involves p190 RhoGAP and ROCK proteins through a GRB2-mediated complex. *Neuron* **36**, 727–738.

72 Swanson AM, DePoy LM and Gourley SL (2017) Inhibiting Rho kinase promotes goal-directed decision making and blocks habitual responding for cocaine. *Nat Commun* **8**, 1861.

73 Suzuki Y, Yamamoto M, Wada H, Ito M, Nakano T, Sasaki Y, Narumiya S, Shiku H and Nishikawa M (1999) Agonist-induced regulation of myosin phosphatase activity in human platelets through activation of Rho-kinase. *Blood* **93**, 3408–3417.

74 Shimokawa H, Hiramori K, Iinuma H, Hosoda S, Kishida H, Osada H, Katagiri T, Yamauchi K, Yui Y, Minamino T *et al.* (2002) Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study. *J Cardiovasc Pharmacol* **40**, 751–761.

75 Masumoto A, Mohri M, Shimokawa H, Urakami L, Usui M and Takeshita A (2002) Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. *Circulation* **105**, 1545–1547.

76 Shimizu T, Fukumoto Y, Tanaka S, Satoh K, Ikeda S and Shimokawa H (2013) Crucial role of ROCK2 in vascular smooth muscle cells for hypoxia-induced pulmonary hypertension in mice. *Arterioscler Thromb Vasc Biol* **33**, 2780–2791.

77 Hartmann S, Ridley AJ and Lutz S (2015) The function of Rho-associated kinases ROCK1 and ROCK2 in the pathogenesis of cardiovascular disease. *Front Pharmacol* **6**, 276.

78 Okamoto R, Li Y, Noma K, Hiroi Y, Liu PY, Taniguchi M, Ito M and Liao JK (2013) FHL2 prevents cardiac hypertrophy in mice with cardiac-specific deletion of ROCK2. *FASEB J* **27**, 1439–1449.

79 Rikitake Y, Oyama N, Wang CY, Noma K, Satoh M, Kim HH and Liao JK (2005) Decreased perivascular fibrosis but not cardiac hypertrophy in ROCK1 + /- haploinsufficient mice. *Circulation* **112**, 2959–2965.

80 Knipe RS, Tager AM and Liao JK (2015) The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis. *Pharmacol Rev* **67**, 103–117.

81 Tybulewicz VL and Henderson RB (2007) Rho family GTPases and their regulators in lymphocytes. *Nat Rev Immunol* **9**, 630–644.

82 Henning SW, Galandrini R, Hall A and Cantrell DA (1997) The GTPase Rho has a critical regulatory role in thymus development. *EMBO J* **16**, 2397–2407.

83 Corre I, Gomez M, Vielkind S and Cantrell DA (2001) Analysis of thymocyte development reveals that the GTPase RhoA is a positive regulator of T cell receptor responses in vivo. *J Exp Med* **194**, 903–914.

84 Yang J-Q, Kalim KW, Li Y, Zhang S, Hinge A, Filippi MD, Zheng Y and Guo F (2016) RhoA orchestrates glycolysis for TH2 cell differentiation and allergic airway inflammation. *J Allergy Clin Immunol* **137**, 231–245.

85 Heasman SJ, Carlin LM, Cox S, Ng T and Ridley AJ (2010) Coordinated RhoA signaling at the leading edge and uropod is required for T cell transendothelial migration. *J Cell Biol* **190**, 553–563.

86 Worthylake RA, Lemoine S, Watson JM and Burridge K (2001) RhoA is rquired for monocyte tail retraction during transendothelial migration. *J Cell Biol* **154**, 147–160.

87 Yoshinaga-Ohara N, Takahashi A, Uchiyama T and Sasada M (2002) Spatiotemporal regulation of moesin phosphorylation and rear release by Rho and serine/threonine phosphatase during neutrophil migration. *Exp Cell Res* **278**, 112–122.

88 Itoh K, Yoshioka K, Akedo H, Uehata M, Ishizaki T and Narumiya S (1999) An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. *Nat Med* **5**, 221–225.

89 Ricker E, Chowdhury L, Yi W & Pernis AB (2016) The RhoA-ROCK pathway in the regulation of T and B cell responses. *F1000Res* **5**, 2295.

90 Schaafsma D, Bos IS, Zuidhof AB, Zaagsma J and Meurs H (2008) The inhaled Rho kinase inhibitor Y-27632 protects against allergen-induced acute bronchoconstriction, airway hyperresponsiveness, and inflammation. *Am J Physiol Lung Cell Mol Physiol* **295**, L214–L219.

91 Chiba Y, Takada Y, Miyamoto S, MitsuiSaito M, Karaki H and Misawa M (1999) Augmented acetylcholine-induced, Rho-mediated Ca2 + sensitization of bronchial smooth muscle contraction in antigen-induced airway hyperresponsive rats. *Br J Pharmacol* **127**, 597–600.

92 Zhu M, Liu PY, Kasahara DI, Williams AS, Verbout NG, Halayko AJ, Fedulov A, Shoji T, Williams ES, Noma K *et al.* (2011) Role of Rho kinase isoforms in murine allergic airway responses. *Eur Respir J* **38**, 841–850.

93 Kasahara DI, Mathews JA, Ninin FM, Wurmbrand AP, Liao JK and Shore SA (2017) Role of ROCK2 in $CD4_+$ cells in allergic airways responses in mice. *Clin Exp Allergy* **47**, 224–235.

94 Biswas PS, Gupta S, Chang E, Song L, Stirzaker RA, Liao JK, Bhagat G and Pernis AB (2010) Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice. *J Clin Invest* **120**, 3280–3295.

95 Lee JH, Zheng Y, von Bornstadt D, Wei Y, Balcioglu A, Daneshmand A, Yalcin N, Yu E, Herisson F, Atalay YB *et al.* (2014) Selective ROCK2 inhibition in focal cerebral ischemia. *Ann Clin Transl Neurol* **1**, 2–14.

96 Zanin-Zhorov A, Weiss JM, Nyuydzefe MS, Chen W, Scher JU, Mo R, Depoil D, Rao N, Liu B, Wei J *et al.* (2014) Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. *Proc Natl Acad Sci USA* **111**, 16814–16819.

97 Flynn R, Paz K, Du J, Reichenbach DK, Taylor PA, Panoskaltsis-Mortari A, Vulic A, Luznik L, MacDonald KK, Hill GR *et al.* (2016) Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. *Blood* **127**, 2144–2154.

98 Rozo C, Chinenov Y, Maharaj RK, Gupta S, Leuenberger L, Kirou KA, Bykerk VP, Goodman SM, Salmon JE and Pernis AB (2017) Targeting the RhoA-ROCK pathway to reverse T-cell dysfunction in SLE. *Ann Rheum Dis* **76**, 740–747.

99 Yang W, Zhou G, Yu T, Chen L, Yu L, Guo Y, Cong Y and Liu Z (2017) Critical role of ROCK2 activity in facilitating mucosal CD4 + T cell activation in inflammatory bowel disease. *J Autoimmun* **89**, 125–138.

100 Zanin-Zhorov A, Weiss JM, Trzeciak A, Chen W, Zhang J, Nyuydzefe MS, Arencibia C, Polimera S, Schueller O, Fuentes-Duculan J *et al.* (2017) Cutting edge: selective oral ROCK2 inhibitor reduces clinical scores in patients with psoriasis vulgaris and normalizes skin pathology via concurrent regulation of IL-17 and IL-10. *J Immunol* **198**, 3809–3814.

101 Cook DR, Rossman KL and Der CJ (2014) Rho guanine nucleotide exchange factors: regulators of Rho GTPase activity in development and disease. *Oncogene* **33**, 4021–4035.

102 Kim TY, Vigil D, Der CJ and Juliano RL (2009) Role of DLC-1, a tumor suppressor protein with RhoGAP

activity, in regulation of the cytoskeleton and cell motility. *Cancer Metastasis Rev* **28**, 77–83.

103 Zohn IM, Campbell SL, Khosravi-Far R, Rossman KL and Der CJ (1998) Rho family proteins and Ras transformation: the RHOad less traveled gets congested. *Oncogene* **17**, 1415–1438.

104 Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C *et al.* (2012) A landscape of driver mutations in melanoma. *Cell* **150**, 251–263.

105 Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker JP, Cheng E, Davis MJ, Goh G, Choi M *et al.* (2012) Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. *Nat Genet* **44**, 1006–1114.

106 Kawazu M, Ueno T, Kontani K, Ogita Y, Ando M, Fukumura K, Yamato A, Soda M, Takeuchi K, Miki Y *et al.* (2013) Transforming mutations of RAC guanosine triphosphatases in human cancers. *Proc Natl Acad Sci USA* **110**, 3029–3034.

107 Yoo HY, Sung MK, Lee SH, Kim S, Lee H, Park S, Kim SC, Lee B, Rho K, Lee JE *et al.* (2014) A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. *Nat Genet* **46**, 371–375.

108 Sakata-Yanagimoto M, Enami T, Yoshida K, Shiraishi Y, Ishii R, Miyake Y, Muto H, Tsuyama N, Sato-Otsubo A, Okuno Y *et al.* (2014) Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. *Nat Genet* **46**, 171–175.

109 Kakiuchi M, Nishizawa T, Ueda H, Gotoh K, Tanaka A, Hayashi A, Yamamoto S, Tatsuno K, Katoh H, Watanabe Y *et al.* (2014) Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. *Nat Genet* **46**, 583–587.

110 Olson MF (2018) Rho GTPases, their post-translational modifications, disease-associated mutations and pharmacological inhibitors. *Small GTPases* **12**, 1–13.

111 Wei L, Surma M, Shi S, Lambert-Cheatham N and Shi J (2016) Novel insights into the roles of Rho kinase in cancer. *Arch Immunol Ther Exp (Warsz)* **64**, 259–278.

112 Sahai E, Ishizaki T, Narumiya S and Treisman R (1999) Transformation mediated by RhoA requires activity of ROCK kinases. *Curr Biol* **9**, 136–145.

113 Kümper S, Mardakheh FK, McCarthy A, Yeo M, Stamp GW, Paul A, Worboys J, Sadok A, Jørgensen C, Guichard S *et al.* (2016) Rho-associated kinase (ROCK) function is essential for cell cycle progression, senescence and tumorigenesis. *Elife* **5**, e12994.

114 Sadok A and Marshall CJ (2014) Rho GTPases: masters of cell migration. *Small GTPases* **5**, e29710.

115 Sanz-Moreno V, Gaggioli C, Yeo M, Albrengues J, Wallberg F, Viros A, Hooper S, Mitter R, Féral CC, Cook M *et al.* (2011) ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma. *Cancer Cell* **20**, 229–245.

116 Rath N, Morton JP, Julian L, Helbig L, Kadir S, McGhee EJ, Anderson KI, Kalna G, Mullin M, Pinho AV *et al.* (2017) ROCK signaling promotes collagen remodeling to facilitate invasive pancreatic ductal adenocarcinoma tumor cell growth. *EMBO Mol Med* **9**, 198–218.

117 Melendez J, Stengel K, Zhou X, Chauhan BK, Debidda M, Andreassen P, Lang RA and Zheng Y (2011) RhoA GTPase is dispensible for actomyosin regulation but is essential for mitosis in primary mouse embryonic fibroblasts. *J Biol Chem* **286**, 15132–15137.

118 Königs V, Jennings R, Vogl T, Horsthemke M, Bachg AC, Xu Y, Grobe K, Brakebusch C, Schwab A, Bähler M *et al.* (2014) Mouse macrophages completely lacking Rho subfamily GTPases (RhoA, RhoB and RhoC) have severe lamelipodial retraction defects, but robust chemotactic navigation and altered motility. *J Biol Chem* **289**, 30772–30784.

119 Ridley AJ (2016) Open questions: what about the "other" Rho GTPases? *BMC Biol* **14**, 64.

120 Ridley AJ (2013) RhoA, RhoB and RhoC have different roles in cancer cell migration. *J Microsc* **251**, 242–249.

121 Adamson P, Paterson HF and Hall A (1992) Intracellular localization of the P21Rho proteins. *J Cell Biol* **119**, 617–627.

122 Pedersen E and Brakebusch C (2012) Rho GTPase function in development: how in vivo model changes our view. *Exp Cell Res* **318**, 1779–1787.

123 Vega FM and Ridley AJ (2016) The RhoB small GTPase in physiology and disease. *Small GTPases* **22**, 1–10.

124 Hakem A, Sanchez-Sweatman O, You-Ten A, Duncan G, Wakeham A, Khokha R and Mak TW (2005) RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis. *Genes Dev* **19**, 1974–1979.

125 Rossman KL, Der CJ and Sondek J (2005) GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors. *Nat Rev Mol Cell Biol* **6**, 167–180.